Ignite Creation Date:
2024-05-11 @ 8:31 AM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06402487
Status:
COMPLETED
Last Update Posted:
2024-05-07
First Post:
2024-04-29
Brief Title:
Propionic Acid in Multiple Sclerosis
Sponsor:
Salzburger Landeskliniken
Organization:
Salzburger Landeskliniken
Study Overview
Official Title:
Propionic Acid in Multiple Sclerosis - a Placebo-controlled Randomized Double-blinded Clinical Trial
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MADAI
Brief Summary:
The purpose of this study is to demonstrate the superiority of propionic acid over placebo as add on treatment in multiple sclerosis MS
Detailed Description:
This is a single-center double-blinded randomized trial One hundred multiple sclerosis MS patients will be randomly assigned in a 21 ratio to receive either 100 mg of propionic acid or a placebo over a period of 90 days Outcome measures will encompass NfL and GFAP levels fatigue scores quality of life assessments and physical examinations Additionally subgroup analysis will involve the evaluation of MRI and MEG data
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None